|
Part of
Arrive early to attend Fluorescent
Proteins in Drug Development, November 13-14
Overview
The ability to detect biological changes at the level of cells and molecules in vivo plays a key role for
future progress in molecular medicine. This leads to a demand for new probes and technologies which
target specific metabolic events on a molecular level. In addition, current technologies are still battling
the challenge to find a clinically suitable imaging modality, which allows to predict efficacy of drugs in
the clinic. Strategies that address these problems are the focus of this conference.
|
Sessions Include:
Presenting Companies:
-
Bioluminescence
-
Preclinical Imaging
-
Imaging in - Neurology
Cardiology
Oncology
|
-
Boehringer Ingelheim Pharma GmbH &
Co.
-
GlaxoSmithKline, UK
-
Harvard Medical School
-
Kodak Molecular Imaging Systems
- Pfizer, Inc.
...and more!
|
|
For more information about this
conference, please contact:
Margit Eder, Ph.D., Conference Director, Cambridge Healthtech
Institute
Phone: 781-972-5478 – Fax: 781-972-5425 - E-mail: meder@healthtech.com
For sponsorship or exhibiting information, please contact:
Carol Dinerstein, Business Development Manager, Cambridge Healthtech
Institute
Phone: 781-972-5471 – Fax: 781-972-5425 – E-mail: dinerstein@healthtech.com
|
